Athenex Inc
F:2MT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its Industry Average (19.1), the stock would be worth €-0.33 (374% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -7 | €0.12 |
0%
|
| Industry Average | 19.1 | €-0.33 |
-374%
|
| Country Average | 22.9 | €-0.39 |
-428%
|
Forward P/E
Today’s price vs future net income
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
A
|
Athenex Inc
F:2MT
|
715.7m EUR | -7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
351.3B USD | 83.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.7B USD | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
161.8B USD | 19 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 27.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 37 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.7B AUD | 31.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.3 |
| Median | 22.9 |
| 70th Percentile | 33.2 |
| Max | 1 826 183.3 |
Other Multiples
Athenex Inc
Glance View
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. The company is headquartered in Buffalo, New York and currently employs 652 full-time employees. The company went IPO on 2017-06-14. The Company’s platforms include Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. Oncology Innovation Platform is engaged in research and development of its drugs. Global Supply Chain Platform is engaged in supplying active pharmaceutical ingredient to clinical and commercial efforts. Commercial Platform includes specialty pharmaceuticals business, and manufacture and marketing of products. The Company’s product pipeline includes Orascovery, Src Kinase Inhibition, Cell Therapy and Arginine Deprivation Therapy. Its lead product candidate Orascovery platform technology is based on the oral P-gp pump inhibitor molecule, encequidar. The Src Kinase inhibition platform technology is based on small molecule compounds including the inhibition of the activity of Src Kinase and the inhibition of tubulin polymerization.
